Sutro Biopharma Inc (STRO)
2.93
+0.01
(+0.34%)
USD |
NASDAQ |
Jun 28, 16:00
2.935
0.00 (0.00%)
After-Hours: 20:00
Sutro Biopharma Research and Development Expense (Annual): 180.42M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 180.42M |
| December 31, 2022 | 137.17M |
| December 31, 2021 | 104.40M |
| December 31, 2020 | 76.96M |
| Date | Value |
|---|---|
| December 31, 2019 | 65.61M |
| December 31, 2018 | 54.26M |
| December 31, 2017 | 54.64M |
| December 31, 2016 | 43.55M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
65.61M
Minimum
2019
180.42M
Maximum
2023
112.91M
Average
104.40M
Median
2021
Research and Development Expense (Annual) Benchmarks
| AnaptysBio Inc | 132.28M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |
| iBio Inc | 10.33M |
| Theriva Biologics Inc | 14.31M |